TY - JOUR
T1 - Towards disease modification in osteoarthritis
AU - Dell'Accio, Francesco
AU - De Bari, Cosimo
PY - 2023/5/15
Y1 - 2023/5/15
N2 - In December 2022, Gerwin et al published in Nature Medicine that the C-terminal portion of angiopoietin-like 3, called LNA043, has chondroprotective and cartilage-regenerative properties. Molecular data from an experimental medicine phase I study suggested potential efficacy in humans. Here, we respond to and complement a commentary from Vincent and Conaghan and discuss unresolved issues and the potential of this molecule as a disease-modifying osteoarthritis drug.
AB - In December 2022, Gerwin et al published in Nature Medicine that the C-terminal portion of angiopoietin-like 3, called LNA043, has chondroprotective and cartilage-regenerative properties. Molecular data from an experimental medicine phase I study suggested potential efficacy in humans. Here, we respond to and complement a commentary from Vincent and Conaghan and discuss unresolved issues and the potential of this molecule as a disease-modifying osteoarthritis drug.
U2 - 10.1016/j.joca.2023.05.002
DO - 10.1016/j.joca.2023.05.002
M3 - Comment/debate
C2 - 37196976
SN - 1063-4584
JO - Osteoarthritis and Cartilage
JF - Osteoarthritis and Cartilage
ER -